ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Circulating FTO Protein Levels and β-Cell Function in Individuals with Different Metabolic Profiles: A Cross- Sectional Study.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obesity and type 2 diabetes mellitus are characterized by insulin resistance and progressive impairment of β-cell function. Fat mass and obesity-associated (FTO) protein, an m6A demethylase involved in metabolic regulation, has been linked to obesity. However, the relationship between circulating FTO protein levels and β-cell function among individuals with different metabolic profiles remains unclear. This study aimed to investigate circulating FTO levels and their relationship with β-cell function, assessed by (HOMA-β), in individuals with newly diagnosed T2D, obese individuals without diabetes, and normal-weight individuals without diabetes. Patients and Methods: This cross-sectional observational study included 82 participants: 39 individuals newly diagnosed with T2D, 23 obese individuals without diabetes, and 20 normal-weight individuals without diabetes. Anthropometric and biochemical parameters, including fasting blood glucose, glycated hemoglobin, fasting insulin, HOMA-IR, and HOMA-β, were assessed. Serum FTO levels were measured using ELISA. Correlation and multiple linear regression analyses were performed to examine the relationship between circulating FTO levels and (HOMA-β). Results: Serum FTO protein levels differed significantly among the three groups (P = 0.002), with the highest levels observed in obese individuals without diabetes. In this group, FTO protein levels were positively correlated with body mass index, fasting insulin, and HOMA-β (P = 0.018, P = 0.040, and P = 0.033, respectively). HOMA-β was also positively correlated with FTO, fasting insulin, and HOMA-IR. However, the positive association between FTO levels and HOMA-β was not statistically significant after adjustment for age, sex, and metabolic status. Conclusions: Circulating FTO levels were highest in obese individuals without diabetes and were positively correlated with HOMA-β in this group. However, this relationship was not independently significant after adjustment for potential confounders. These findings provide preliminary evidence of a relationship between circulating FTO and β-cell function in the context of obesity, while the cross-sectional design precludes causal or temporal inferences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.